Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

venetoclax 152Cytarabine 114Cyclophosphamide 110Specimen Handling 101Azacitidine 99fludarabine 89Biopsy 76Rituximab 48Methotrexate 45Daunorubicin 44fludarabine phosphate 42Vincristine 38Dexamethasone 37Magnetic Resonance Spectroscopy 36Injections 34Decitabine 34blinatumomab 31Granulocyte Colony-Stimulating Factor 30Mycophenolic Acid 29Whole-Body Irradiation 28Prednisone 28Idarubicin 28ibrutinib 27Tacrolimus 27Etoposide 27Doxorubicin 27Busulfan 27Melphalan 24acalabrutinib 23Mercaptopurine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panzyga × Other hematologic neoplasm × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡